QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD Disclosure

0
QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD Disclosure

QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On December 7, 2018, the Company issued a press release providing the Company’s comments on a California State Court ruling in the Company's ongoing litigation with Beckman Coulter Inc. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 of this current report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.


QUIDEL CORP /DE/ Exhibit
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1     Quidel Contact: Media and Investors Contact:Quidel Corporation Quidel CorporationRandy Steward Ruben ArguetaChief Financial Officer (858) 646-8023(858) 552-7931 [email protected] COMMENTS ON CALIFORNIA COURT RULINGSAN DIEGO–(BUSINESS WIRE)-Dec 7,…
To view the full exhibit click here

About QUIDEL CORPORATION (NASDAQ:QDEL)

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain.